Study of Talabostat in Advanced Melanoma

Completed · Phase 2

Conditions studied: Melanoma, Skin Cancer

In brief

The purpose of this study is to assess the antitumor activity and safety of talabostat in patients with metastatic melanoma.

Key facts

Study ID

NCT00083239

Run by

Point Therapeutics

Last updated by the study team

2007-06-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed melanoma that is metastatic (unresectable Stage IV per AJCC 2002)
• Patients with measurable disease defined as at least one measurable index lesion with clearly defined margins
• ECOG Performance Status of 0, 1, or 2
• Expected survival ≥12 weeks
• Written informed consent

You may not qualify if…

• More than 1 prior chemotherapy or biotherapy regimen for Stage IV melanoma
• Radiation therapy to >50% of the bone marrow. Patients must not have had prior radiotherapy to index lesions unless they have clearly progressive disease in this site or there is measurable disease outside the area of prior radiation.
• Clinically significant laboratory abnormalities
• CNS metastases
• Any malignancy within the 5 years immediately prior to the first dose of study medication with the exception of basal cell or non-metastatic squamous cell carcinoma of the skin, and carcinoma in-situ of the cervix
• The need for chronic (i.e., >7 days) oral or intravenous corticosteroid therapy
• Any comorbidity or condition which, in the opinion of the investigator, may interfere with the assessments and procedures of this protocol
• Patients who are within 30 days of chemotherapy, radiation therapy, immunotherapy, or other investigational medication for melanoma. Patients must have recovered from all of the side effects of treatment in order to be enrolled.
• Pregnant or lactating women.

Where it is running

• Emory University/Winship Cancer Institute — Atlanta, Georgia, United States
• University of Chicago — Chicago, Illinois, United States
• University of Michigan — Ann Arbor, Michigan, United States
• Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire, United States
• University of Pittsburgh — Pittsburgh, Pennsylvania, United States
• Mary Crowley Medical Research Center — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.